Civik Thomas 4

What Happened

• Civik Thomas, a director of Repare Therapeutics, reported a disposition to the issuer of 7,500 common shares on 2026-01-28 (transaction code D). The Form 4 lists the price as N/A, but footnotes state the shares were transferred pursuant to an Arrangement Agreement in which each share was exchanged for $2.20 in cash plus one non-transferable contingent value right (CVR). The cash component equals roughly $16,500 (7,500 x $2.20).

Key Details

• Transaction date: 2026-01-28; filing date: 2026-01-28 (filed timely).
• Reported transaction type: D (Disposition to the issuer, i.e., shares surrendered/cancelled to the company in connection with an acquisition).
• Consideration per footnotes: $2.20 cash per share + one CVR per share (non-transferable).
• Shares owned after the transaction: not reported in the provided data.
• Relevant footnotes: F1/F2 describe the Arrangement Agreement under which XenoTherapeutics, Xeno Acquisition Corp. and XOMA Royalty Corporation acquired all outstanding Repare shares for $2.20/share plus one CVR.

Context

• Dispositions to the issuer commonly occur when a company is acquired and outstanding shares are cashed out or converted under the deal terms; this is typically a transaction tied to the corporate event rather than an open-market sale by the insider. The inclusion of CVRs means holders may have additional contingent upside tied to future milestones; CVRs are non-transferable per the filing.